57 related articles for article (PubMed ID: 9353320)
1. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598.
Koshelnick Y; Ehart M; Hufnagl P; Heinrich PC; Binder BR
J Biol Chem; 1997 Nov; 272(45):28563-7. PubMed ID: 9353320
[TBL] [Abstract][Full Text] [Related]
2. Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.
Montuori N; Pesapane A; Rossi FW; Giudice V; De Paulis A; Selleri C; Ragno P
Transl Med UniSa; 2016 Nov; 15():15-21. PubMed ID: 27896223
[TBL] [Abstract][Full Text] [Related]
3. Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures.
Ge Y; Siegel AP; Jordan R; Naumann CA
Biophys J; 2014 Nov; 107(9):2101-11. PubMed ID: 25418095
[TBL] [Abstract][Full Text] [Related]
4. Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs.
Chang YC; Wu CZ; Cheng CW; Chen JS; Chang LC
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895906
[TBL] [Abstract][Full Text] [Related]
5. Tumor Microenvironment in Glioma Invasion.
Tamai S; Ichinose T; Tsutsui T; Tanaka S; Garaeva F; Sabit H; Nakada M
Brain Sci; 2022 Apr; 12(4):. PubMed ID: 35448036
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.
Zhai BT; Tian H; Sun J; Zou JB; Zhang XF; Cheng JX; Shi YJ; Fan Y; Guo DY
J Transl Med; 2022 Mar; 20(1):135. PubMed ID: 35303878
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.
Gonias SL
Am J Physiol Cell Physiol; 2021 Oct; 321(4):C721-C734. PubMed ID: 34406905
[TBL] [Abstract][Full Text] [Related]
8. Serine Proteases and Chemokines in Neurotrauma: New Targets for Immune Modulating Therapeutics in Spinal Cord Injury.
Beladi RN; Varkoly KS; Schutz L; Zhang L; Yaron JR; Guo Q; Burgin M; Hogue I; Tierney W; Dobrowski W; Lucas AR
Curr Neuropharmacol; 2021; 19(11):1835-1854. PubMed ID: 33632104
[TBL] [Abstract][Full Text] [Related]
9. Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression.
Li XG; Hong XY; Wang YL; Zhang SJ; Zhang JF; Li XC; Liu YC; Sun DS; Feng Q; Ye JW; Gao Y; Ke D; Wang Q; Li HL; Ye K; Liu GP; Wang JZ
EMBO Rep; 2019 Jun; 20(6):. PubMed ID: 31085626
[TBL] [Abstract][Full Text] [Related]
10. The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes.
Hayward CP; Liang M; Tasneem S; Soomro A; Waye JS; Paterson AD; Rivard GE; Wilson MD
PLoS One; 2017; 12(3):e0173991. PubMed ID: 28301587
[TBL] [Abstract][Full Text] [Related]
11. Urokinase receptor and resistance to targeted anticancer agents.
Gonias SL; Hu J
Front Pharmacol; 2015; 6():154. PubMed ID: 26283964
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1-dependent and -independent uPAR signaling pathways contribute to ganglioside GT1b induced early apoptosis in A549 lung cancer cells.
Hwang JH; Sung JS; Kim JM; Chung YH; Park JS; Lee SH; Jang IS
Am J Cancer Res; 2014; 4(6):801-10. PubMed ID: 25520869
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.
Bao YN; Cao X; Luo DH; Sun R; Peng LX; Wang L; Yan YP; Zheng LS; Xie P; Cao Y; Liang YY; Zheng FJ; Huang BJ; Xiang YQ; Lv X; Chen QY; Chen MY; Huang PY; Guo L; Mai HQ; Guo X; Zeng YX; Qian CN
Cell Cycle; 2014; 13(12):1958-69. PubMed ID: 24763226
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.
Santibanez JF
ISRN Dermatol; 2013; 2013():597927. PubMed ID: 23984088
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/β-catenin signaling is enhanced in irradiated medulloblastoma cells.
Asuthkar S; Gondi CS; Nalla AK; Velpula KK; Gorantla B; Rao JS
J Biol Chem; 2012 Jun; 287(24):20576-89. PubMed ID: 22511755
[TBL] [Abstract][Full Text] [Related]
16. Regulation of urokinase expression at the posttranscription level by lung epithelial cells.
Shetty SK; Marudamuthu AS; Abernathy D; Shetty RS; Shetty P; Fu J; Idell S; Bhandary YP; Ji H; Liu MC; Shetty S
Biochemistry; 2012 Jan; 51(1):205-13. PubMed ID: 22166006
[TBL] [Abstract][Full Text] [Related]
17. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells.
Gogineni VR; Nalla AK; Gupta R; Dinh DH; Klopfenstein JD; Rao JS
Cancer Lett; 2011 Dec; 313(1):64-75. PubMed ID: 21945852
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma.
Malla RR; Gopinath S; Gondi CS; Alapati K; Dinh DH; Gujrati M; Rao JS
Cancer Gene Ther; 2011 Jun; 18(6):419-34. PubMed ID: 21394106
[TBL] [Abstract][Full Text] [Related]
19. Activation of the stress protein response inhibits the STAT1 signalling pathway and iNOS function in alveolar macrophages: role of Hsp90 and Hsp70.
Howard M; Roux J; Lee H; Miyazawa B; Lee JW; Gartland B; Howard AJ; Matthay MA; Carles M; Pittet JF
Thorax; 2010 Apr; 65(4):346-53. PubMed ID: 20388761
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cell signalling by uPAR.
Smith HW; Marshall CJ
Nat Rev Mol Cell Biol; 2010 Jan; 11(1):23-36. PubMed ID: 20027185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
